Ameriprise Financial Inc Biocryst Pharmaceuticals Inc Transaction History

Ameriprise Financial Inc

$375 Billion
Q4 2024

A detailed history of Ameriprise Financial Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Ameriprise Financial Inc holds 1,720,581 shares of BCRX stock, worth $14.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,720,581

Previous 1,772,501 2.93%

Holding current value

$14.7 Million

Previous $13.5 Million 3.96%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$7.03 - $8.43 $364,997 - $437,685	-51,920 Reduced 2.93%	1,720,581 $12.9 Million
Q3 2024 Nov 14, 2024	SELL	$6.41 - $8.69 $596,912 - $809,230	-93,122 Reduced 4.99%	1,772,501 $13.5 Million
Q2 2024 Aug 14, 2024	SELL	$4.13 - $6.79 $1.94 Million - $3.19 Million	-469,568 Reduced 20.11%	1,865,623 $11.5 Million
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $5.49 Million - $8.58 Million	1,122,212 Added 92.52%	2,335,191 $11.9 Million
Q4 2023 Feb 14, 2024	BUY	$4.98 - $6.77 $2.8 Million - $3.81 Million	563,066 Added 86.64%	1,212,979 $7.27 Million
Q3 2023 Nov 14, 2023	BUY	$6.71 - $7.92 $46,137 - $54,457	6,876 Added 1.07%	649,913 $4.6 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $2.15 Million - $2.72 Million	308,648 Added 92.3%	643,037 $4.53 Million
Q1 2023 May 15, 2023	SELL	$7.94 - $11.84 $3.95 Million - $5.9 Million	-497,936 Reduced 59.82%	334,389 $2.79 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $3.29 Million - $4.45 Million	313,623 Added 60.46%	832,325 $9.56 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $2.92 Million - $4 Million	270,419 Added 108.92%	518,702 $6.54 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $899,893 - $2.04 Million	114,055 Added 84.97%	248,283 $2.63 Million
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $1.55 Million - $2.65 Million	134,228 New	134,228 $2.18 Million
Q3 2021 Nov 15, 2021	SELL	$14.21 - $17.65 $674,733 - $838,074	-47,483 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$9.5 - $17.24 $27,084 - $49,151	-2,851 Reduced 5.66%	47,483 $751,000
Q1 2021 May 17, 2021	SELL	$7.37 - $13.61 $149,168 - $275,466	-20,240 Reduced 28.68%	50,334 $512,000
Q4 2020 Feb 12, 2021	BUY	$3.37 - $8.61 $67,231 - $171,769	19,950 Added 39.41%	70,574 $525,000
Q3 2020 Nov 16, 2020	SELL	$3.43 - $5.53 $100,643 - $162,261	-29,342 Reduced 36.69%	50,624 $174,000
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $151,935 - $448,609	79,966 New	79,966 $381,000
Q1 2020 May 15, 2020	SELL	$1.6 - $4.11 $174,430 - $448,068	-109,019 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $34,612 - $75,103	21,769 Added 24.95%	109,019 $377,000
Q3 2019 Nov 14, 2019	BUY	$2.5 - $3.73 $218,125 - $325,442	87,250 New	87,250 $250,000
Q1 2019 May 15, 2019	SELL	$7.38 - $9.72 $872,485 - $1.15 Million	-118,223 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$6.51 - $9.6 $769,631 - $1.13 Million	118,223 New	118,223 $954,000

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

167M

Call Options Held

728K

Put Options Held

989K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.59B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account

Ameriprise Financial Inc Biocryst Pharmaceuticals Inc Transaction History